An interesting note from the detailed interim judgement in the ongoing patent dispute between Galderma and Mylan.
As part of the proceedings Mylan looked at the on-going Oracea sales and projected that Galderma can expect to receive around $260 million in 2011.
MYLAN PHARMACEUTICALS INC., v. GALDERMA LABORATORIES, L.P.; et. al.
Mylan projected that Oracea’s brand dollars for the period of January 2011 through December 2011 would be approximately $258.1 million.
Oracea’s sales growth was listed as
- 2007: $43 million
- 2008: $80.4 million
- 2009: $155.3 million
- 2010: $236.7 million
Obviously a highly successful product for Galderma.
As I noted recently, the battle still has some way to go. As neither Galderma nor Mylan prevailed with all of their claims, further arguments are required from each party.
